Education
About Us
Working with TipRanks
Follow Us
Icon Plc (ICLR)
:ICLR
ICLR Analyst Ratings
Moderate Buy
10 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ICLR Stock 12 Month Forecast
Average Price Target
$207.23
▲(13.84% Upside)
| Highest Price Target$236.00 | Average Price Target$207.23 | Lowest Price Target$172.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Evercore ISI
$220
Buy
20.86%
Upside
Reiterated
10/27/25
TR | OpenAI - 4o
$201→$198
Buy
8.77%
Upside
Reiterated
10/26/25
AI Generated ArticleAI Generated Article
UBS
$240→$220
Buy
20.86%
Upside
Reiterated
10/24/25
Robert W. Baird
$218→$220
Buy
20.86%
Upside
Reiterated
10/24/25
Bank of America Securities
―
Buy
―
Reiterated
10/24/25
TD Cowen
$183→$172
Hold
-5.51%
Downside
Reiterated
10/24/25
Hold Rating for Icon Amid Margin Pressure and Revenue ChallengesWe come away still concerned on '26 ests, w/ mgmt. expecting margin pressure from pass-throughs to continue into 4Q and next year. Margin pressure from pricing is another headwind to '26 that hasn't been felt yet. Further, ICLR expects continued elevated cancels for 4Q, which could extend into '26 before normalizing, impacting '26 rev growth. Combined, we see risk to cons. '26 revs & adj. EBITDA.
Truist Financial
$234→$231
Buy
26.90%
Upside
Reiterated
10/24/25
Leerink Partners
$235→$220
Buy
20.86%
Upside
Reiterated
10/23/25
Optimistic Buy Rating for Icon Amid Market Concerns and Margin QuestionsWe think the ICLR negative stock reaction is due to worries on pricing/gross margins that are not new, and, in our minds, likely overblown relative to the valuation. We remain positive on the risk/reward and think the improved gross awards/ RFP flow should help re-establish a better growth profile. The quarter did not include any negative surprises and the improved gross bookings wins/book-to-bill was encouraging. We were not expecting cancelations to moderate yet, so were are not surprised to see both the 3Q result/4Q embedded expectation. As for pricing and subsequent margins - it is a key variable into next year's growth and something we are actively watching. We had concerns over margin trajectory before today and our concerns are still there. The important factor to us is they haven't gotten meaningfully worse nor are they reflected in the valuation.
William Blair
―
Buy
―
Reiterated
10/23/25
Icon's Resilience and Growth Potential Justifies Buy Rating Despite Mixed Q3 PerformanceWe expect this pricing dynamic and management’s view on its implications for margins in 2026 to be a key area of focus on tomorrow’s call given the company’s historic strong margin expansion performance across macro environments. We anticipate other key topics of discussion will be recent customer sentiment following better-than-feared updates on tariffs and drug pricing reforms and the relative performance of ICON’s biotech customer base in the quarter given improved funding andMedpace’s (MEDP $546.74; Market Perform) impressive beat and raise. We reiterate our Outperform rating while we wait for more detail on these dynamics on tomorrow’s call.
J.P. Morgan
$175
Hold
-3.86%
Downside
Reiterated
10/23/25
Barclays
$190
Hold
4.38%
Upside
Reiterated
10/23/25
Mizuho Securities
$225
Buy
23.61%
Upside
Reiterated
09/16/25
Jefferies
$220→$175
Hold
-3.86%
Downside
Downgraded
09/08/25
Rothschild & Co Redburn
$184→$236
Buy
29.65%
Upside
Upgraded
09/03/25
Citi
$225→$200
Hold
9.87%
Upside
Downgraded
08/21/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
$220
Buy
20.86%
Upside
Reiterated
10/27/25
TR | OpenAI - 4o
$201→$198
Buy
8.77%
Upside
Reiterated
10/26/25
AI Generated ArticleAI Generated Article
UBS
$240→$220
Buy
20.86%
Upside
Reiterated
10/24/25
Robert W. Baird
$218→$220
Buy
20.86%
Upside
Reiterated
10/24/25
Bank of America Securities
―
Buy
―
Reiterated
10/24/25
TD Cowen
$183→$172
Hold
-5.51%
Downside
Reiterated
10/24/25
Hold Rating for Icon Amid Margin Pressure and Revenue ChallengesWe come away still concerned on '26 ests, w/ mgmt. expecting margin pressure from pass-throughs to continue into 4Q and next year. Margin pressure from pricing is another headwind to '26 that hasn't been felt yet. Further, ICLR expects continued elevated cancels for 4Q, which could extend into '26 before normalizing, impacting '26 rev growth. Combined, we see risk to cons. '26 revs & adj. EBITDA.
Truist Financial
$234→$231
Buy
26.90%
Upside
Reiterated
10/24/25
Leerink Partners
$235→$220
Buy
20.86%
Upside
Reiterated
10/23/25
Optimistic Buy Rating for Icon Amid Market Concerns and Margin QuestionsWe think the ICLR negative stock reaction is due to worries on pricing/gross margins that are not new, and, in our minds, likely overblown relative to the valuation. We remain positive on the risk/reward and think the improved gross awards/ RFP flow should help re-establish a better growth profile. The quarter did not include any negative surprises and the improved gross bookings wins/book-to-bill was encouraging. We were not expecting cancelations to moderate yet, so were are not surprised to see both the 3Q result/4Q embedded expectation. As for pricing and subsequent margins - it is a key variable into next year's growth and something we are actively watching. We had concerns over margin trajectory before today and our concerns are still there. The important factor to us is they haven't gotten meaningfully worse nor are they reflected in the valuation.
William Blair
―
Buy
―
Reiterated
10/23/25
Icon's Resilience and Growth Potential Justifies Buy Rating Despite Mixed Q3 PerformanceWe expect this pricing dynamic and management’s view on its implications for margins in 2026 to be a key area of focus on tomorrow’s call given the company’s historic strong margin expansion performance across macro environments. We anticipate other key topics of discussion will be recent customer sentiment following better-than-feared updates on tariffs and drug pricing reforms and the relative performance of ICON’s biotech customer base in the quarter given improved funding andMedpace’s (MEDP $546.74; Market Perform) impressive beat and raise. We reiterate our Outperform rating while we wait for more detail on these dynamics on tomorrow’s call.
J.P. Morgan
$175
Hold
-3.86%
Downside
Reiterated
10/23/25
Barclays
$190
Hold
4.38%
Upside
Reiterated
10/23/25
Mizuho Securities
$225
Buy
23.61%
Upside
Reiterated
09/16/25
Jefferies
$220→$175
Hold
-3.86%
Downside
Downgraded
09/08/25
Rothschild & Co Redburn
$184→$236
Buy
29.65%
Upside
Upgraded
09/03/25
Citi
$225→$200
Hold
9.87%
Upside
Downgraded
08/21/25
Best Analysts Covering Icon
1 Month
xxx
Success Rate
24/41 ratings generated profit
Average Return
+1.12%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.54% of your transactions generating a profit, with an average return of +1.12% per trade.
3 Months
xxx
Success Rate
18/32 ratings generated profit
Average Return
+2.74%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +2.74% per trade.
1 Year
2 Years
xxx
Success Rate
26/41 ratings generated profit
Average Return
+11.60%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.41% of your transactions generating a profit, with an average return of +11.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ICLR Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
1
0
0
0
0
Buy
21
31
27
35
21
Hold
11
12
8
8
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
43
35
43
25
Each month's total comprises the sum of three months' worth of ratings.
ICLR Financial Forecast
ICLR Stock Forecast FAQ
What is ICLR’s average 12-month price target, according to analysts?
Based on analyst ratings, Icon Plc’s 12-month average price target is 207.23.
What is ICLR’s upside potential, based on the analysts’ average price target?
Icon Plc has 13.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ICLR a Buy, Sell or Hold?
Icon Plc has a consensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 0 sell ratings.
What is Icon Plc’s price target?
The average price target for Icon Plc is 207.23. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $236.00 ,the lowest forecast is $172.00. The average price target represents 13.84% Increase from the current price of $182.03.
The highest analyst price target is $236.00 ,the lowest forecast is $172.00. The average price target represents 13.84% Increase from the current price of $182.03.
What do analysts say about Icon Plc?
Icon Plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of ICLR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.